•
Mar 31, 2023

Dover Q1 2023 Earnings Report

Dover's Q1 2023 results were released, showcasing revenue growth and solid execution amidst inflationary and foreign currency translation headwinds.

Key Takeaways

Dover reported a 1% increase in revenue to $2.1 billion for Q1 2023, with organic revenue up by 3%. GAAP diluted EPS increased by 4% to $1.63, while adjusted diluted EPS rose by 2% to $1.94. The company maintains its full-year adjusted EPS guidance.

Revenue grew across the majority of Dover's portfolio due to the recovery in global supply chains and solid demand.

New order intake was healthy and encouraging for the rest of the year.

Margin performance was as expected, with four out of five segments improving year-over-year margins.

The company is on track to deliver its full-year cash flow target by liquidating inventory.

Total Revenue
$2.08B
Previous year: $2.05B
+1.3%
EPS
$1.94
Previous year: $1.9
+2.1%
Gross Profit
$747M
Previous year: $743M
+0.5%
Cash and Equivalents
$272M
Previous year: $290M
-6.1%
Free Cash Flow
$193M
Previous year: -$26.7M
-822.6%
Total Assets
$10.8B
Previous year: $10.5B
+2.9%

Dover

Dover

Dover Revenue by Segment

Forward Guidance

Dover expects full year 2023 GAAP EPS in the range of $7.81 to $8.01 (adjusted EPS of $8.85 to $9.05), based on full year revenue growth of 3% to 5%.

Positive Outlook

  • Dover is on track to deliver its full year cash flow target as it liquidates inventory in concert with a normalization of its backlog.
  • Demand conditions in attractive industrial markets remain solid.
  • Bookings are healthy.
  • Elevated backlog levels, especially in some longer-cycle businesses, provide good visibility to the full year forecast.
  • Prior investments in automation, productivity projects, and cost actions are delivering the benefits necessary to offset inflationary input costs.

Challenges Ahead

  • Inflationary headwinds.
  • Foreign currency translation headwinds.
  • Pumps and Process Solutions segment margins were lower due to the mix effect of lower biopharma volumes.
  • Mixed macroeconomic backdrop.
  • Diligently monitoring customers’ plans.

Revenue & Expenses

Visualization of income flow from segment revenue to net income